font measurement
Moderna Covid-19 vaccine.
Yuichi Yamazaki / Getty Photographs
accident
It’s set to report second-quarter earnings on Thursday as the corporate sits getting ready to an unsure transition into the business Covid-19 vaccine market, with questions looming over how a lot demand stays for the vaccines three years after their launch.
Analysts count on
accident
(Inventory ticker: MRNA) reported a lack of $3.93 per share for the quarter, on income of simply $308 million, based on FactSet. The corporate achieved revenues of $4.7 billion in the identical quarter final yr.
Whereas the Covid-19 vaccine has develop into one of many best-selling medicine of all time, with $18.4 billion in gross sales in 2022, Moderna has no different marketed merchandise. The corporate stated it expects Covid-19 vaccine gross sales of not less than $5 billion in 2023. Analysts count on $7.1 billion in gross sales this yr, based on FactSet.
Moderna shares are down practically 40% this yr, as a substitute
Normal & Poor’s 500
practically 20%.
Earlier this yr, Moderna stated it anticipated Covid-19 vaccine gross sales of between $200 million and $300 million within the second quarter. Industrial gross sales of the vaccine are anticipated to start this fall, when the corporate will launch an up to date model of the vaccine. Because the first injections got in late 2020, all Covid-19 vaccines in the USA have been paid for by the federal authorities. That ended earlier this yr; The federal government is at the moment working by way of its remaining provides.
Moderna’s Covid-19 vaccine competitor
Pfizer
(Inventory ticker: PFE), in its earnings presentation on Tuesday, confused the uncertainty within the US Covid-19 vaccine market, saying that uptake to date this yr was decrease than anticipated, however that Pfizer’s market share was barely bigger than anticipated. Pfizer stated it could make value cuts if gross sales of its Covid-19 vaccine and therapeutics fall in need of expectations by the top of the yr.
The scenario in Moderna is totally different. The Covid-19 vaccine, Spikevax, was the corporate’s first product marketed. Whereas it has a large pipeline, together with plenty of late-stage applications, no product launches are anticipated this yr.
Important Modena pipeline applications embody a vaccine for respiratory syncytial virus, which could possibly be launched in 2024 and would compete with new RSV vaccines from Pfizer and
GSK
(GSK). The corporate can be anticipating new knowledge on its messenger RNA-based flu vaccine later this yr, and it lately launched a Part 3 examine in collaboration with
merck
(MRK) her promising Most cancers remedy, mRNA-4157.
Moderna plans to carry investor Name at 8 a.m. on a Thursday to debate the monetary outcomes.
Write to Josh Nathan Kazis at josh.nathan-kazis@barrons.com
